sellWeak cluster of 410b5-1 plan
Ellen Rosenberg sold $958k of FOLD
Chief Legal Officer at AMICUS THERAPEUTICS, INC.. 95,621 shares at an average of $10.02, traded Nov 24, 2025, filed Nov 26, 2025.
Warning score
24Value
$958k
95,621 shares
Holdings after
507,710
-18% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +24Trade size$958k at market
- +5Share of holdings soldSold 18% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001193125-25-301017, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 24, 2025 | MOption exercise Common Stock10b5-1 | +25,000 | $6.10 | $153k | 532,710 | Nov 26, 2025 |
| Nov 24, 2025 | MOption exercise Common Stock10b5-1 | +11,000 | $5.13 | $56k | 543,710 | Nov 26, 2025 |
| Nov 24, 2025 | SOpen-market sale Common Stock10b5-1 | -36,000 | $10.06 | $362k | 507,710 | Nov 26, 2025 |
| Nov 25, 2025 | MOption exercise Common Stock10b5-1 | +36,000 | $5.13 | $185k | 543,710 | Nov 26, 2025 |
| Nov 25, 2025 | SOpen-market sale Common Stock10b5-1 | -36,000 | $10.00 | $360k | 507,710 | Nov 26, 2025 |
| Nov 26, 2025 | MOption exercise Common Stock10b5-1 | +23,621 | $5.13 | $121k | 531,331 | Nov 26, 2025 |
| Nov 26, 2025 | SOpen-market sale Common Stock10b5-1 | -23,621 | $10.00 | $236k | 507,710 | Nov 26, 2025 |
| Nov 24, 2025 | MOption exercise Stock Options (right to buy)derivative10b5-1 | -25,000 | $0.00 | $0 | 0 | Nov 26, 2025 |
| Nov 24, 2025 | MOption exercise Stock Options (right to buy)derivative10b5-1 | -11,000 | $0.00 | $0 | 59,621 | Nov 26, 2025 |
| Nov 25, 2025 | MOption exercise Stock Options (right to buy)derivative10b5-1 | -36,000 | $0.00 | $0 | 23,621 | Nov 26, 2025 |
| Nov 26, 2025 | MOption exercise Stock Options (right to buy)derivative10b5-1 | -23,621 | $0.00 | $0 | 0 | Nov 26, 2025 |
Related signals
Other insiders at AMICUS THERAPEUTICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 19Weak | AMICUS THERAPEUTICS, INC. | Bradley L Campbell President and CEO | $323k 22,500 shares | -2% | |
| 15Weak | AMICUS THERAPEUTICS, INC. | Bradley L Campbell President and CEO | $1.1M 75,000 shares | -7% | |
| 18Weak | AMICUS THERAPEUTICS, INC. | David Michael Clark Chief People Officer | $363k 25,642 shares | -9% | |
| 17Weak | AMICUS THERAPEUTICS, INC. | David Michael Clark Chief People Officer | $282k 25,643 shares | -9% | |
| 21Weak | AMICUS THERAPEUTICS, INC. | Bradley L Campbell President and CEO | $846k 77,926 shares | -6% | |
| 16Weak | AMICUS THERAPEUTICS, INC. | Bradley L Campbell President and CEO | $146k 14,587 shares | -1% | |
| 16Weak | AMICUS THERAPEUTICS, INC. | Bradley L Campbell President and CEO | $147k 14,587 shares | -1% | |
| 23Weak | AMICUS THERAPEUTICS, INC. | David Michael Clark Chief People Officer | $259k 25,643 shares | -8% | |
| 22Weak | AMICUS THERAPEUTICS, INC. | Jeff Castelli Chief Development Officer | $774k 76,158 shares | -15% | |
| 8Weak | AMICUS THERAPEUTICS, INC. | David Michael Clark Chief People Officer | $244k 25,643 shares | -7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.